EODData

MEMBERSHIP REGISTER LOG IN

NYSE, RCUS: Arcus Biosciences Inc

27 Feb 26 15:59
LAST:

20.37

CHANGE:
 0.83		OPEN:
19.54		HIGH:
20.44		ASK:
0.00		VOLUME:
1.26M
CHG(%):
4.25		PREV:
19.54		LOW:
19.50		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
27 Feb 2619.5020.4419.5020.371.76M
26 Feb 2619.8920.9719.2119.541.24M
25 Feb 2620.3020.8420.0820.27775.5K
24 Feb 2619.0921.2019.0920.191.63M
23 Feb 2619.2219.7518.5218.851.25M
20 Feb 2619.1919.6118.9418.991.15M
19 Feb 2619.2219.6518.8619.481.15M
18 Feb 2618.9819.7218.9819.431.12M
17 Feb 2618.7619.4218.6519.24953.3K
13 Feb 2620.1720.5318.8118.921.45M

PROFILE

Name:Arcus Biosciences Inc
About:Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Sector:Healthcare
Industry:Biotechnology
Address:3928 Point Eden Way, Hayward, CA, United States, 94545
Website:https://www.arcusbio.com
CUSIP:03969F109
CIK:0001724521
ISIN:US03969F1093
FIGI:BBG00DQD26W3

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-7.35 
Forward P/E:-5.98 
PEG Ratio:-0.27 
Price to Sales:11.92 
Price to Book:5.68 
Profit Margin:-1.42 
Operating Margin:-5.46 
Return on Assets:-0.21 
Return on Equity:-0.68 
EPS Ratio:-3.14 
Revenue:240.0M 
Shares:106.43M 
Market Cap:2.168B 

TECHNICAL INDICATORS

MA5:19.842.7%
MA10:19.534.3%
MA20:20.260.5%
MA50:21.606.0%
MA100:20.942.8%
MA200:15.4831.6%
STO9:64.68
STO14:55.68
RSI14:45.68
WPR14:-39.44
MTM14:-0.76
ROC14:-0.04 
ATR:1.17 
Week High:21.204.1%
Week Low:18.5210.0%
Month High:23.5015.4%
Month Low:18.5231.6%
Year High:26.4029.6%
Year Low:6.50213.4%
Volatility:62.64